This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) (“Geron” or “the Company”) for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the May 13, 2014 lead plaintiff deadline. Investors who have suffered significant financial losses, and who want to discuss their options, can contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by emailing
Geron@hbsslaw.com or by calling 510-725-3000.
The securities fraud class-action lawsuit, filed on March 14, 2014, on behalf of investors who purchased Geron stock between June 16, 2013 and March 11, 2014 (the “Class Period”), alleges that the company failed to disclose key information to its investors regarding the halting of its sponsored clinical trials by the FDA.
For more information about the suit, visit
The complaint alleges that Geron, a clinical stage biopharmaceutical company, misrepresented or failed to disclose that persistent low-grade liver function test (LFT) abnormalities had been observed in the study of imetelstat – the company’s sole product candidate. According to the complaint, the company received notice from the FDA on March 12, 2014, that its work with imetelstat had been placed on full clinical hold, greatly affecting Geron’s sponsored clinical trials; Geron failed to disclose this information to investors. This hold was due to the potential risk of chronic liver injury following long-term exposure to imetelstat. Following this news, Geron shares declined $2.71 per share, more than 61 percent, to close at $1.69 per share on March 12, 2014.
“When a company fails to disclose information that an investor would want to know, it puts stakeholders at risk, especially when the information involves the majority of their product,” said Mr. Kathrein. “Our investigation focuses on Geron’s knowledge of persistent low-grade LFT levels, and its concern about these levels.”